GlassScriptPhysician profile
Sohail Merchant
NPI 1275160939
$600.87
in general payments reported to CMS, 2019-2025
12 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.61 · 2023: $91.51 · 2024: $364 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $158.71 | 2024-2025 | Bexsero, Rotarix |
| Sanofi-Aventis U.S. LLC | $158.44 | 2024-2025 | |
| Pfizer INC. | $69.13 | 2022-2024 | |
| Phadia US INC. | $38.65 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $34.15 | 2023 | Breztri |
| Cranial Technologies, INC | $30.16 | 2025 | Doc Band |
| Amgen INC. | $19.66 | 2022 | |
| Merck Sharp & Dohme LLC | $19.66 | 2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Abbvie INC. | $19.37 | 2023 | |
| Supernus Pharmaceuticals, INC. | $18.06 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2023 | Nuedexta |
| Seqirus USA INC | $17.23 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.